Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$28.86K$28.86Kderived−64.7% vs Q4 2024 Net Income-$488.53K-$488.53KderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$11,907N/M Operating Incomederived-$465,914N/M Operating Cash Flowderived-$219,818N/M Free Cash Flowderived-$219,818— Margins · derivedGross margin-41.3%−147.0 pt vs Q4 2024
Operating margin-1614.2%−1395.7 pt vs Q4 2024
Net margin-1692.5%−1410.5 pt vs Q4 2024
ended Dec 31, 2025 · filed May 20, 2026 · 140 d after period end